BigGo Finance reports women in the CagriSema trial lost more weight than the study population as a whole.
Recap by typeshit. Full story at finance.biggo.com.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
She points to work shown at ADA 2026 and published in Nature Communications suggesting semaglutide may improve epigenetic aging markers.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Alicia Butterfield claims Anthem denied her Zepbound once the drug got her below morbid obesity. A Los Angeles judge stayed her case pending arbitration.
Loading…